Previous studies showed a large inpatient burden of psoriasis in the United States. Less is known about the hospital readmission for psoriasis.
To determine the patterns and predictors of hospital readmission rates for psoriasis.
We analyzed data from the 2012-2014 Nationwide Readmissions Database, a representative sample of hospital readmissions in the United States.
Among 2606 admissions for psoriasis, 216 had ≥1 readmissions for psoriasis (prevalence [95% confidence interval]: 8.3% [6.6%-10.0%]) and 918 for all-causes (35.2% [32.2%-38.3%]). The mean annual cost of first readmission for any reason was $3,500,141, with $8,357,961 for subsequent readmissions. In multivariable regression models, readmission for psoriasis was associated with ≥6 day-long index hospitalization (adjusted hazard ratio [95% confidence interval]: 1.82 [1.06-3.12]), teaching hospital (1.93 [1.13-3.31]), comorbid skin infection (2.13 [1.11-4.08]), and hospitalization in the autumn (4.51 [2.54-8.00]), but inversely associated with other infections (0.49 [0.26-0.92]). Readmissions for psoriasis increased from 2012 to 2014 (1.93 [1.26-2.93]).
No data on psoriasis characteristics.
Inpatients with psoriasis had high rates of readmission overall but low rates of readmission for psoriasis per se. A subset of psoriasis patients was hospitalized repeatedly and responsible for most inpatients costs. Future interventions are needed to lower readmission rates among psoriasis patients.Le texte complet de cet article est disponible en PDF.
Key words : comorbidity, emergency, epidemiology, health services, hospitalization, psoriasis, readmission
Abbreviations used : CI, HR, ICD-9-CM, IQR, NRD, OR, US
| Funding sources: This publication was made possible with support from the Dermatology Foundation, which was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
| Conflicts of interest: None disclosed.
| IRB approval status: The Northwestern University Institutional Review Board approved the study.
| Reprints not available from the authors.